Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 222

1.

Conjugation Approach To Produce a Staphylococcus aureus Synbody with Activity in Serum.

Lainson JC, Fuenmayor MF, Johnston SA, Diehnelt CW.

Bioconjug Chem. 2015 Oct 21;26(10):2125-32. doi: 10.1021/acs.bioconjchem.5b00420. Epub 2015 Sep 14.

PMID:
26365100
2.

Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages.

Jubrail J, Morris P, Bewley MA, Stoneham S, Johnston SA, Foster SJ, Peden AA, Read RC, Marriott HM, Dockrell DH.

Cell Microbiol. 2016 Jan;18(1):80-96. doi: 10.1111/cmi.12485. Epub 2015 Sep 2.

PMID:
26248337
3.

Immunosignature: Serum Antibody Profiling for Cancer Diagnostics.

Chapoval AI, Legutki JB, Stafford P, Trebukhov AV, Johnston SA, Shoikhet YN, Lazarev AF.

Asian Pac J Cancer Prev. 2015;16(12):4833-7.

4.

Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis.

Gibson JF, Johnston SA.

Fungal Genet Biol. 2015 May;78:76-86. doi: 10.1016/j.fgb.2014.11.006. Epub 2014 Dec 12.

5.

Peptide based diagnostics: are random-sequence peptides more useful than tiling proteome sequences?

Navalkar KA, Johnston SA, Stafford P.

J Immunol Methods. 2015 Feb;417:10-21. doi: 10.1016/j.jim.2014.12.002. Epub 2014 Dec 11.

PMID:
25497701
6.

Epitope identification from fixed-complexity random-sequence peptide microarrays.

Richer J, Johnston SA, Stafford P.

Mol Cell Proteomics. 2015 Jan;14(1):136-47. doi: 10.1074/mcp.M114.043513. Epub 2014 Nov 3.

7.

'Division of labour' in response to host oxidative burst drives a fatal Cryptococcus gattii outbreak.

Voelz K, Johnston SA, Smith LM, Hall RA, Idnurm A, May RC.

Nat Commun. 2014 Oct 17;5:5194. doi: 10.1038/ncomms6194.

8.

The immunosignature of canine lymphoma: characterization and diagnostic application.

Johnston SA, Thamm DH, Legutki JB.

BMC Cancer. 2014 Sep 8;14:657. doi: 10.1186/1471-2407-14-657.

9.

Scalable high-density peptide arrays for comprehensive health monitoring.

Legutki JB, Zhao ZG, Greving M, Woodbury N, Johnston SA, Stafford P.

Nat Commun. 2014 Sep 3;5:4785. doi: 10.1038/ncomms5785.

PMID:
25183057
10.

Immunosignature system for diagnosis of cancer.

Stafford P, Cichacz Z, Woodbury NW, Johnston SA.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3072-80. doi: 10.1073/pnas.1409432111. Epub 2014 Jul 14.

11.

Application of immunosignatures for diagnosis of valley fever.

Navalkar KA, Johnston SA, Woodbury N, Galgiani JN, Magee DM, Chicacz Z, Stafford P.

Clin Vaccine Immunol. 2014 Aug;21(8):1169-77. doi: 10.1128/CVI.00228-14. Epub 2014 Jun 25.

12.

Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis.

Sabiiti W, Robertson E, Beale MA, Johnston SA, Brouwer AE, Loyse A, Jarvis JN, Gilbert AS, Fisher MC, Harrison TS, May RC, Bicanic T.

J Clin Invest. 2014 May;124(5):2000-8. doi: 10.1172/JCI72950. Epub 2014 Apr 17.

13.

Could immunosignatures technology enable the development of a preventative cancer vaccine?

Shen L, Hansen DT, Johnston SA, Legutki JB.

Expert Rev Vaccines. 2014 May;13(5):577-9. doi: 10.1586/14760584.2014.897616. Epub 2014 Mar 18.

PMID:
24641768
14.

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE Jr, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY.

MAbs. 2014 May-Jun;6(3):577-618. doi: 10.4161/mabs.28421. Epub 2014 Mar 3.

15.

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.

Bruce JY, Kolesar JM, Hammers H, Stein MN, Carmichael L, Eickhoff J, Johnston SA, Binger KA, Heideman JL, Perlman SB, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2014 Mar;73(3):485-93. doi: 10.1007/s00280-013-2373-9. Epub 2014 Jan 12.

16.

Immunosignatures can predict vaccine efficacy.

Legutki JB, Johnston SA.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18614-9. doi: 10.1073/pnas.1309390110. Epub 2013 Oct 28.

17.

In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.

Budsberg SC, Stoker AM, Johnston SA, Liska W, Reno LR, Cook JL.

Am J Vet Res. 2013 Sep;74(9):1198-205. doi: 10.2460/ajvr.74.9.1198.

PMID:
23977892
18.

A technology for developing synbodies with antibacterial activity.

Domenyuk V, Loskutov A, Johnston SA, Diehnelt CW.

PLoS One. 2013;8(1):e54162. doi: 10.1371/journal.pone.0054162. Epub 2013 Jan 23.

19.

Cancer goal: Vaccine is cause for optimism.

Johnston SA.

Nature. 2013 Jan 17;493(7432):304. doi: 10.1038/493304c. No abstract available.

PMID:
23325200
20.

Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen.

Johnston SA, May RC.

Cell Microbiol. 2013 Mar;15(3):403-11. doi: 10.1111/cmi.12067. Epub 2012 Nov 30. Review.

PMID:
23127124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk